76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Adaptive Biotechnologies Corp
Closed
12.11 1
Overview
Share price change
24h
Min
11.57
Max
12.39
Income | 3.9M -30M |
|---|---|
Sales | 5M 52M |
EPS | -0.2 |
Profit margin | -56.881 |
Employees | 619 |
EBITDA | -3.3M -30M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | -1% downside |
Next Earnings | 31 Jul 2025 |
|---|
Market Cap | 422M 1.6B |
|---|---|
Previous open | 11.11 |
Previous close | 12.11 |
Technical Score
By Trading Central
Confidence
Very Strong Bullish Evidence
Adaptive Biotechnologies Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Adaptive Biotechnologies Corp Forecast
Price Target
By TipRanks
-1% downside
12 Months Forecast
Average 11.86 USD -1%
High 15 USD
Low 9 USD
Based on 8 Wall Street analysts offering 12 month price targets forAdaptive Biotechnologies Corp - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
